Long-Term Survival in Metastatic Melanoma Patients Treated with Sequential Biochemotherapy: Report of a Phase II Study

REFERENCES

• Ries L. A., Kosary C. L., MD, Hankey B. F. SEER Cancer Statistic Review 1973–1994. NIH publication no. 97-2789, National, Cancer Institute, Bethesda 1997
   Google Scholar
• Greenlee S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 2000. CA Cancer J. Clin. 2000; 50: 19–27, [CSA]
   Google Scholar
• Berwick M., Halpern A. Melanoma epidemiology. Curr. Opin. Oncol. 1997; 9: 178–185, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Ahmed I. Malignant melanoma: prognostic indicators. Mayo. Clin. Proc. 1997; 72: 336–361, [CSA]
   Google Scholar
• Buttner P., Garbe C., Bertz J., Burg G., d'Hoed B., et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 1995; 75: 2484–2491, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Morton D. L. Current management of malignant melanoma. Ann. Surg. 1990; 212: 123–127, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Balch C. M., Soong S. J., Gershenwald J. E., Thompson J. F., Reintg D. S., Cascinelli N., Urist M., McMasters K. M., Ross M. I., Kirkwood J. M., Atkins M. B., Thompson J. A., Coit D. G., Byrd D., Desmond R., Zhang Y., Liu P. Y., Lyman G. H., Morabito A. Prognostic factor analysis of 17,600 melanoma patients: validation of the American Committee on Cancer Melanoma staging system. J. Clin. Oncol. 2001; 19: 3622–3634, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Barth A., Wanek L. A., Morton D. L. Prognostic factors in 1,521 melanoma patients with distant metastases. J. Am. Coll. Surg. 1995; 181: 193–201, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Guerry D., Schuchter L. M. Disseminated melanoma: is there a new standard therapy?. N. Engl. J. Med. 1992; 327: 560–561, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shadendorf D. Is there a standard for the palliative treatment of melanoma?. Onkologie 2002; 25: 74–76, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lee S. M., Betticher D. C., Tratcher N. Melanoma chemotherapy. Br. Med. Bull. 1995; 51: 609–617, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chapman P. B., Einhorn L. H., Meyers M. L., Saxman S., Destro A. N., Panageas K. S., Begg C. B., Agarwala S. S., Schuchter L. M., Ernstoff M. S., Houghton A. N., Kirkwood J. M. Phase III multicenter randomized trial of the Dartmount regimen versus dacarbazine in patients with metastatic melanoma. J. Cli. Oncol. 1999; 17: 2745–2751, [CSA]
   PubMed Web of Science ®Google Scholar
• Chiarion Sileni V., Nortilli R., Aversa S. M., Paccagnella A., Medici M., Corti L., Favaretto A. G., Cetto G. L., Monfardini S. PhaseII randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. Melanoma. Res. 2001; 11: 189–196, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Flaherty L. E., Atkins M., Sosman J., Weiss G., Clark J. I., Margolin K., Dutcher J., Gordon M. S., Lotze M., Mier J., Sorokin P., Fisher R. I., Appel C., Du W. Outpatient biochemotherapy with interleukin-2 and interferon-alfa in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J. Clin. Oncol. 2001; 19: 3194–3202, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Richards J. M., Metha N., Ramming K., Skosey P. Sequential chemo-immunotherapy in the treatment of metastatic melanoma. J. Clin. Oncol. 1992; 10: 1338–1343, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Neri B., Doni L., Gemelli M T, Fulignati C., Turrini M., Di Cello V., Maleci M., Mottola A., Ponchetti R., Raugei A., Valsuani G., Cini G. Phase II trial of weekly intravenous Gemcitabine administration with Interferon and Interleukine-2 immunotherapy for metastatic renal cell carcinoma. J. Urology 2002; 168: 956–958, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mitchell M. S. Combination of anticancer drugs and immunotherapy. Cancer Immunol Immunother 2003; 52(11)686–692, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gehan E. A. The determination of the number of patients required in the follow-up trial of a new chemotherapeutic agent. J. Chron. Dis. 1961; 13: 346–353, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Flaherty L. E. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastin and DTIC alone in patients with metastatic melanoma. Cancer. J. Sci. Am. 2000; 6: 15–20, [CSA]
   PubMedGoogle Scholar
• Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Seipp C. A., Einhorn J. H., White D. E., Steinberg S. M. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. Clin. J. Oncol. 1999; 17: 968–975, [CSA]
   PubMed Web of Science ®Google Scholar
• Koduri J., Baumann M. A. Cisplatin and dacarbazine with or without subcutaneous interleukin-2 and interferon alfa-2b in advanced melanoma outpatients. J. Clin. Oncol. 2002; 20: 3560–3571, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Atkins M. B., Lee S., Flaherty L. E. A prospective randomized phase III trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine (CVD), IL-2 and interferon alpha –2b versus CVD alone in patients with metastatic melanoma (E3695). An ECOG coordinated intergroup trial. Proc. Am. Soc. Clin. Oncol. 2003; 22: 2847–2853, [CSA]
   Google Scholar
• Legha S. S., Ring S., Eton O., Bedikian A., Buzaid A. C., Plager C., Papadoupolos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vincristine, dacarbazine, interferon-α and interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 1998; 16: 1752–1759, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Buzaid A. C. Biochemotherapy for advanced melanoma. Critical Reviews in Oncology 2002; 44: 103–108, [CSA], [CROSSREF]
   Google Scholar
• Eton O., Legha S. S., Bedikian A. Y., Lee J. J., Buzaid A. C., Hodges C., Ring S. E., Papadopulos N. E., Plager C., East M. J., Zhan F., Benjamin R. S. Sequential biochemotherapy versus chemotherapy for metastatic melanoma results from a phase III randomized trial. J. Clin. Oncol. 2002; 20: 2045–2052, [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Buzaid A. C. Biochemotherapy for advanced melanoma. Oncology Hematol. 2002; 44: 103–108, [CSA]
   Web of Science ®Google Scholar